Payment overview · 2025
General Payments
$507.26
25 reported records · 10 companies
Healthcare provider profile · identity verified
Eric C Troyer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LANDIS, NC · NPI 1962409748
Verified facts
What the public records show
CMS Open Payments records show Eric C Troyer, M.D. received $507.26 in general payments during 2025 across 25 reported records.
Indivior Inc. accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brixadi, Qulipta, Quviviq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
Braeburn Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRIXADI as an associated drug or biological on 15883 records involving 5757 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brixadi by this doctor in 2024.
IDORSIA PHARMACEUTICALS US INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUVIVIQ as an associated drug or biological on 2281 records involving 1911 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Quviviq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $121.33 | 23.9% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $105.60 | 20.8% | 5 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $91.52 | 18.0% | 5 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $43.64 | 8.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.14 | 8.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.37 | 6.6% | 2 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $19.68 | 3.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.89 | 3.5% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $16.60 | 3.3% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $16.49 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $507.26 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $121.33 | 5 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $91.52 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.78 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.78 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $41.82 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.14 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRIXADI brixadi |
2025 | Brixadi | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Quviviq quviviq |
2025 | Quviviq | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Braeburn Inc. Exact reporting entity; no affiliate inference |
2025 | BRIXADI open payments reported associated product |
CMS Open Payments — General Payments 15883 supporting records · 5757 recipient NPIs · example record 1249056386 |
Brixadi · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| IDORSIA PHARMACEUTICALS US INC Exact reporting entity; no affiliate inference |
2025 | QUVIVIQ open payments reported associated product |
CMS Open Payments — General Payments 2281 supporting records · 1911 recipient NPIs · example record 1243392023 |
Quviviq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 321 | 40 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 230 | 25 |
| Omeprazole | Omeprazole | 199 | 37 |
| Oxycodone Hcl | Oxycodone Hcl | 172 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 167 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 37 |
| Lisinopril | Lisinopril | 162 | 31 |
| Gabapentin | Gabapentin | 153 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 33 |
| Meloxicam | Meloxicam | 133 | 33 |
| Furosemide | Furosemide | 113 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 103 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 99 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 98 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 14 |
| Mirtazapine | Mirtazapine | 64 | 15 |
| Sertraline Hcl | Sertraline Hcl | 64 | 11 |
| Etodolac | Etodolac | 62 | 18 |
| Ibuprofen | Ibuprofen | 60 | 19 |
| Linzess | Linaclotide | 60 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 13 |
| Trazodone Hcl | Trazodone Hcl | 60 | 12 |
| Clonidine Hcl | Clonidine Hcl | 54 | 13 |
| Buspirone Hcl | Buspirone Hcl | 53 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 16 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 12 |
| Losartan Potassium | Losartan Potassium | 47 | 13 |
| Buprenorphine Hcl | Buprenorphine Hcl | 46 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 46 | 11 |
| Eliquis | Apixaban | 45 | suppressed |
| Mupirocin | Mupirocin | 45 | 14 |
| Promethazine Hcl | Promethazine Hcl | 45 | 16 |
| Diclofenac Potassium | Diclofenac Potassium | 44 | suppressed |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 12 |
| Azithromycin | Azithromycin | 39 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 37 | 11 |
| Prednisone | Prednisone | 36 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 22 |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Simvastatin | Simvastatin | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 16 |
| Levofloxacin | Levofloxacin | 29 | 26 |
| Metformin Hcl | Metformin Hcl | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | 11 |
| Brixadi | Buprenorphine | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Quviviq | Daridorexant Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $507.26 · 25 records | Indivior Inc. | BRIXADI, IBSRELA, JATENZO, MAVYRET, MOUNJARO, QULIPTA, Quviviq, SUBLOCADE, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND, Zubsolv | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brixadi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error